OBJECTIVE: This study aims to determine the burden of illness imposed by severe sepsis in Switzerland by evaluating the direct and indirect patient-related costs for critically ill patients with severe sepsis. METHODS: In order to estimate the direct costs a retrospective analysis was undertaken using records from 61 adult patients treated in three intensive care units (ICUs) in three different University hospitals in Switzerland, in 2001. Resource use was determined by a bottom up approach and valued using centre-specific unit costs for medication, nutrition, blood products, disposables and official tariffs for laboratory and microbiology analysis, diagnostic services, and clinical procedures. By adding centre-specific personnel and basic bed (hotel) costs total direct costs in the ICU were calculated. Indirect costs resulting from unfitness for work, early retirement, and premature death were calculated using official Swiss statistics for the years 1998-2000. RESULTS: The mean total direct costs for a severely septic patient are CHF 41,790 (+/- 33,222 CHF) or CHF 3244 (+/- 757 CHF) per day. Nonsurvivors cause significantly higher costs than survivors (CHF 45,956 vs. CHF 37,759, p <0.001). The total intensive care costs in Switzerland due to severe sepsis amount to CHF 146-355 million. Indirect costs were estimated to range from CHF 347 to 844 million (predominantly due to premature death). Consequently the burden of illness of severe sepsis can be estimated to range from CHF 493 to 1199 million per year in Switzerland (1 CHF = 0.662 Euro in 2001). CONCLUSION: Patients suffering from severe sepsis in Switzerland have a high mortality rate and spend a prolonged time in the ICU, leading to high direct and indirect costs. Particularly productivity losses due to premature death represent a considerable burden to the Swiss society.
OBJECTIVE: This study aims to determine the burden of illness imposed by severe sepsis in Switzerland by evaluating the direct and indirect patient-related costs for critically illpatients with severe sepsis. METHODS: In order to estimate the direct costs a retrospective analysis was undertaken using records from 61 adult patients treated in three intensive care units (ICUs) in three different University hospitals in Switzerland, in 2001. Resource use was determined by a bottom up approach and valued using centre-specific unit costs for medication, nutrition, blood products, disposables and official tariffs for laboratory and microbiology analysis, diagnostic services, and clinical procedures. By adding centre-specific personnel and basic bed (hotel) costs total direct costs in the ICU were calculated. Indirect costs resulting from unfitness for work, early retirement, and premature death were calculated using official Swiss statistics for the years 1998-2000. RESULTS: The mean total direct costs for a severely septic patient are CHF 41,790 (+/- 33,222 CHF) or CHF 3244 (+/- 757 CHF) per day. Nonsurvivors cause significantly higher costs than survivors (CHF 45,956 vs. CHF 37,759, p <0.001). The total intensive care costs in Switzerland due to severe sepsis amount to CHF 146-355 million. Indirect costs were estimated to range from CHF 347 to 844 million (predominantly due to premature death). Consequently the burden of illness of severe sepsis can be estimated to range from CHF 493 to 1199 million per year in Switzerland (1 CHF = 0.662 Euro in 2001). CONCLUSION:Patients suffering from severe sepsis in Switzerland have a high mortality rate and spend a prolonged time in the ICU, leading to high direct and indirect costs. Particularly productivity losses due to premature death represent a considerable burden to the Swiss society.
Authors: Bogdan Tiru; Ernest K DiNino; Abigail Orenstein; Patrick T Mailloux; Adam Pesaturo; Abhinav Gupta; William T McGee Journal: Pharmacoeconomics Date: 2015-09 Impact factor: 4.981
Authors: Renata de S B Fróes; Ana Teresa Pugas Carvalho; Antonio Jose de V Carneiro; Adriana Maria Hilu de Barros Moreira; Jessica P L Moreira; Ronir R Luiz; Heitor S de Souza Journal: Eur J Health Econ Date: 2017-05-18
Authors: Sidneia Sousa Santos; Milena Karina Coló Brunialti; Larissa de Oliveira Cavalcanti Peres Rodrigues; Ana Maria Alvim Liberatore; Ivan Hong Jun Koh; Vanessa Martins; Francisco Garcia Soriano; Csaba Szabo; Reinaldo Salomão Journal: Biomolecules Date: 2022-06-04
Authors: Alejandro Álvaro-Meca; María A Jiménez-Sousa; Dariela Micheloud; Ainhoa Sánchez-Lopez; María Heredia-Rodríguez; Eduardo Tamayo; Salvador Resino Journal: Popul Health Metr Date: 2018-02-12
Authors: Maria C Souza; Denise M Fonseca; Alexandre Kanashiro; Luciana Benevides; Tiago S Medina; Murilo S Dias; Warrison A Andrade; Giuliano Bonfá; Marcondes A B Silva; Aline Gozzi; Marcos C Borges; Ricardo T Gazzinelli; José C Alves-Filho; Fernando Q Cunha; João S Silva Journal: Front Cell Infect Microbiol Date: 2017-04-07 Impact factor: 5.293